The Inherited Skin Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Inherited Skin Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Inherited Skin Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Inherited Skin Disorders and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Inherited Skin Disorders by 16 companies/universities/institutes. The top development phase for Inherited Skin Disorders is preclinical with six drugs in that stage. The Inherited Skin Disorders pipeline has 16 drugs in development by companies and two by universities/ institutes. Some of the companies in the Inherited Skin Disorders pipeline products market are: DermaXon, Kamari Pharma and Haltex Therapeutics.
The key targets in the Inherited Skin Disorders pipeline products market include Cytochrome P450 26B1, Filaggrin, and Epidermal Growth Factor Receptor ERB1.
The key mechanisms of action in the Inherited Skin Disorders pipeline product include Transient Receptor Potential Cation Channel Subfamily V Member 3 Blocker with two drugs in Phase I. The Inherited Skin Disorders pipeline products include four routes of administration with the top ROA being Topical and seven key molecule types in the Inherited Skin Disorders pipeline products market including Small Molecule, and Recombinant Protein.
Inherited Skin Disorders overview
Inherited skin disorders encompass a diverse group of genetic conditions affecting the skin’s structure, function, or development. These disorders can manifest as a range of symptoms, including abnormalities in pigmentation, texture, or the presence of certain growths or lesions. Examples of inherited skin disorders include epidermolysis bullosa, ichthyosis, and albinism. These conditions often result from mutations in specific genes responsible for skin development and maintenance.
For a complete picture of Inherited Skin Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
